757 Intratumoral delivery CD40 agonist antibody via novel nanofluidic drug-eluting seed reduced tumor burden of murine pancreatic ductal adenocarcinoma

Background

Pancreatic adenocarcinoma (PDAC) is associated with extremely poor prognosis and a 5-year survival rate of 10% and remains a lethal malignancy. Surgical resection and combination with chemoradiotherapy are the current standard-of-care options, may improve long-term survival in localized disease; however, the majority of patients are diagnosed at advanced stage. The incorporation of immunotherapy in the treatment algorithm...